Evidence map›Paper›PMID 35599264›Full record

ArticleMedical oncology (Northwood, London, England)2022

A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen.

Farshid Dayyani, Kit Tam, Edward J Kim, Samuel Ejadi, Jennifer Valerin, Thomas H Taylor, May T Cho

Open access · greenAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Farshid DayyaniDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, 200 S Manchester Ave, Orange, CA, 92868, USA. fdayyani@hs.uci.edu.ORCID http://orcid.org/0000-0002-4970-5189
Kit TamDivision of Hematology and Oncology, Department of Medicine, University of California at Davis, Sacramento, CA, USA.
Edward J KimDivision of Hematology and Oncology, Department of Medicine, University of California at Davis, Sacramento, CA, USA.
Samuel EjadiDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, 200 S Manchester Ave, Orange, CA, 92868, USA.
Jennifer ValerinDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, 200 S Manchester Ave, Orange, CA, 92868, USA.
Thomas H TaylorDepartment of Epidemiology, University of California Irvine, Irvine, CA, USA.
May T ChoDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, 200 S Manchester Ave, Orange, CA, 92868, USA.
University of California, Irvine · USUniversity of California, Davis · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

TAS-102 is approved for treatment of refractory metastatic gastroesophageal carcinoma (mGEC). This study sought to determine whether the combination of TAS-102 with irinotecan (TASIRI) was safe and effective in previously treated mGEC. This was a single-arm phase 1b study for patients (pts) with mGEC previously treated with at least one line of fluoropyrimidine and platinum-containing regimen. TAS-102 was given at 25 mg/m

Indexed as

AdenocarcinomaEsophageal NeoplasmsIrinotecanStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDrug CombinationsHumansPlatinumPyrrolidinesThymineTrifluridineDrug CombinationsIrinotecanPlatinumPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationChemotherapyGastric cancerSurvival

Identifiers

PMID35599264
PMCPMC9769492
OpenAlexW4281286564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.